homeBanner

Harnessing Innate Immunity for Health
INmune Bio, Inc. is developing therapies that harness the patient’s immune system to treat cancer. The company has two product platforms. INKmune, primes patient’s NK cells (natural killer cells) to kill cancer. INB03 is an innate immune system check-point inhibitor that targets myeloid derived suppressor cells (MDSC) in the tumor microenvironment that produce an immunosuppressive shield that prevents the patient’s immune system from attacking the cancer. Both products can be used alone, together or in combination with other cancer and immune-oncology therapies. Ultimately, our goal is to harness the patient’s immune system to better attack their cancer. The best way to beat cancer is to include the patient’s immune system in the battle.

aboutIcon

ABOUT US
INmuneBio

INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.

LEARN MORE

stayTunedIcon

NEWS
Stay Tuned

WHY
INmune

Experienced management team with a proven track record.
Patented and leading science in the area of NK immunotherapy.
INKmune is an off-the-shelf product that allows patient’s NK cells to better see, target and kill cancer.